<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Results of allogeneic hematopoietic stem cell transplantation (HCT) to treat advanced <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) remain poor due to excessive relapse and transplant-related mortality </plain></SENT>
<SENT sid="1" pm="."><plain>To improve transplant outcome in this patient population, 43 patients (median age, 46.1 years) with high-risk or advanced lymphoid (n = 5) or <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancy</z:e> (n = 38) were prospectively enrolled on a pilot trial of cytoreduction with intravenous <z:chebi fb="0" ids="28901">busulfan</z:chebi> and melphalan followed by an unmodified HLA-A, -B, and -DRbeta1-matched related (n = 18) or unrelated (n = 25) HCT </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> (GVHD) prophylaxis consisted of tacrolimus and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Thirty-four patients had &gt; or = 5% blasts at the time of HCT; 12 of these had &gt; 20% blasts </plain></SENT>
<SENT sid="4" pm="."><plain>Seventeen patients had unfavorable cytogenetics, 8 patients underwent transplantation for <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> or <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo>, and 4 patients had relapsed after a previous allogeneic transplantation </plain></SENT>
<SENT sid="5" pm="."><plain>Although mucositis was the most significant regimen-related toxicity, requiring the addition of folinic acid rescue and failure to receive <z:hpo ids='HP_0000001'>all</z:hpo> 4 doses of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> in 23 patients, the nonrelapse mortality at 30 and 100 days was low at 0% and 16%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The cumulative incidence of grade II-IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD was 24%, and that of extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD was 7% </plain></SENT>
<SENT sid="7" pm="."><plain>With a minimum follow-up of 18 months, the estimated 3-year overall survival is 37% and the estimated disease-free survival (DFS) is 33% </plain></SENT>
<SENT sid="8" pm="."><plain>For 18 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (&lt; or = <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-2</z:e>) or high-risk <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo>, the estimated 3 year DFS is 61% </plain></SENT>
<SENT sid="9" pm="."><plain>These data demonstrate the curative potential of this regimen in patients with high-risk <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
</text></document>